INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- SamsungBioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ...
SamsungBioepis and Teva have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), which is SamsungBioepis’s biosimilar to Soliris. Samsung ...
(RTTNews) - SamsungBioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement for EPYSQLI, SamsungBioepis biosimilar to ...
INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- SamsungBioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market Report, marking the eighth edition of the Quarterly ...
Results that may be inaccessible to you are currently showing.